source
- Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year.BioSpace · 1h ago↗ source
- Layoffs hit over 1,300 workers across seven biopharma M&A deals in 2026Workforce reductions this year have affected at least seven biopharma companies that recently completed mergers or acquisitions, eliminating a minimum of 1,359 jobs, according to BioSpace data. Th…